Contract development of intranasal vaccines and contract manufacturing under GMP.
Libra Medicina Co., Ltd. is the exclusive agent in Japan for Mycenax, a CRO/CDMO specialized in biotechnology in Taiwan.
By ensuring consistent DS and DP manufacturing within the same facility, the need for multiple contract management, material transportation, and technology transfer is minimized!
Our company is the exclusive agent in Japan providing contract manufacturing and GMP contract manufacturing (CRO/CMO) services for biopharmaceuticals from Mycenax Biotech Inc. We offer contract development and manufacturing services that cater to a wide range of modalities, including monoclonal antibodies (mAb), multi-specific antibodies, antibody-drug conjugates (ADC), enzyme preparations, recombinant proteins, cell therapy products, and plasmid DNA. We conduct strict manufacturing management based on PIC/S GMP, and with an integrated system environment of LIMS/QMS, we ensure quality assurance throughout the entire product lifecycle. 【Features】 ■ A highly reliable manufacturing system that meets regulatory requirements ■ Support for minimizing manufacturing risks and rapid development through a consistent manufacturing system for active ingredients and formulations ■ Flexible process adaptation in dedicated manufacturing facilities that accommodate multiple cell lines \ For more details, please check "Download Catalog" /
Inquire About This Product
basic information
For more details, please download the catalog or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please download the catalog or feel free to contact us.
catalog(2)
Download All CatalogsCompany information
Libra Medicina Co., Ltd. aims to contribute to the improvement of health and quality of life for people around the world by being involved in the creation of innovative pharmaceuticals and medical devices through development support services and licensing activities, delivering hope to patients suffering from serious diseases.